Enanta, Novartis deal

Enanta granted Novartis exclusive, worldwide rights to develop and commercialize preclinical HCV product EDP-239. The HCV non-structural protein 5A (NS5A) inhibitor has IND approval from FDA; a timeline for Phase I testing was not disclosed. ...